credits TheGaurdian
The clinical trials of the COVID-19 vaccine ‘Covovax’ are in a complicated stage of completion in India, and therefore the Serum Institute of India (SII) hopes to launch it by September, said its CEO Adar Poonawalla.
In September 2020, Novavax announced a producing agreement with SII for its COVID-19 vaccine candidate NVX-CoV2373.
The trial of Novavax’s coronavirus vaccine in India is probably going to conclude by November, said Poonawalla in talks with CNBC-TV18.
The vaccine candidate ‘NVX-CoV2373’ demonstrated one hundred per cent protection against moderate and severe disease, 90.4 per cent efficacy overall, and met the first endpoint in its PREVENT-19 pivotal Phase 3 trial, Novavax said during a statement on Flag Day . The study enrolled 29,960 participants across 119 sites within the US and Mexico to guage efficacy, safety and immunogenicity of the vaccine, it added.
Novavax President and Chief military officer Stanley C Erck said that, “Today, Novavax is one step closer to addressing the critical and protracted global public health need for extra COVID-19 vaccines. It also added that these clinical results reinforce NVX-CoV2373 is extremely effective and offers complete protection against both moderate and severe COVID-19 infection.”
As per reports, the Novavax vaccine are often stored in standard refrigerators, making it easier to distribute. The vaccine was effective against several variants, including the one first detected within the UK that’s dominant within the US, and in high-risk populations including the elderly and other people with other health problems.